Incyte makes $750M upfront payment for rights to German cancer drug

//Incyte makes $750M upfront payment for rights to German cancer drug

Incyte makes $750M upfront payment for rights to German cancer drug

Incyte Corp. will make an upfront payment of $750 million to MorphoSys AG, and purchase another $150 million of stock in the German drug developer, under the terms of a collaboration and licensing agreement the biotech companies signed Monday. The agreement calls for the two companies to work together to further develop and commercialize an xperimental therapy, called tafasitamab, that MorphoSys has had under development for cancers linked to B cell malignancies. The deal, including the equity…

Article by [author-name] (c) Health Care News - Health Care News Headlines | Bizjournals.com - Read full story here.

By | 2020-01-13T21:58:19+00:00 January 13th, 2020|Healthcare|

About the Author: